Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well. Doses as high as 700 mg/m2 every other week appear to be no more toxic, so we will try to determine if 500 mg/m2 and 750 mg/m2 given every other week can work better. We do not know if it will help. We can use what we learn from this research study to help other people with the same disease.

• Head and Neck
• Squamous Cell Cancer

• Biological: cetuximab
  Cetuximab 500 mg/m2 IV over 2 hours every other week
  Other Name: Erbitux
• Biological: cetuximab
  Cetuximab 750 mg/m2 IV over 3 hours every other week
  Other Name: Erbitux

• Active Comparator: 1
  Cetuximab 500 mg/m2 IV over 2 hours every other week
  Intervention: Biological: cetuximab
• Active Comparator: 2
  Cetuximab 750 mg/m2 IV over 3 hours every other week
  Intervention: Biological: cetuximab

Inclusion Criteria:

• signed informed consent and HIPAA authorization
• histologically confirmed squamous cell cancer of the head and neck
• At least 21 days must have elapsed from the administration of prior chemotherapy for recurrent/metastatic disease.
• measurable disease as defined by RECIST
• ECOG PS ≤ 2
• Adequate hematologic function as defined by an ANC > or = to 1200/mm3 , and a platelet count ≥ 100,000 obtained within 14 days prior to enrollment.
• Adequate hepatic function as defined by t. bilirubin ≤ 1.5 mg/dl, transaminases & alk phos ≤ 5x ULN obtained within 14 days prior to enrollment.
• Adequate renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance >40 mL/minute.
• Women of childbearing potential must agree to use an accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study and have a negative pregnancy test within 7 days prior to registration. If a male and sexually active, the patient agrees to use effective contraception.
• Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center.
• Patients with treated CNS metastases may be eligible if they have fully recovered from radiation therapy, surgery or steroids that were prescribed for CNS metastases.

Exclusion Criteria:

• Known, uncontrolled CNS metastases. CT/MRI of the brain is not required unless CNS metastases are suspected clinically.
• prior cetuximab therapy in the setting of recurrence or refractory disease
• Other active invasive malignancies, other than non-melanoma skin cancers or in situ cervical cancer.
• Concurrent treatment with other anti-cancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, or targeted therapy.
• Ongoing or active clinically serious infection > CTCAE Grade 2 requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia,(patients with stable rate-controlled atrial fibrillation may be eligible) or other medical condition that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study, or psychiatric illness/social situations that would limit compliance with study requirements.
• elective or planned major surgery to be performed during the course of the trial
• pregnant or lactating women
• employees of the investigator or study center w/ direct involvement in this study or other studies under the direction of the or study center, as well as family member of the employees
• More than two prior cytotoxic regimens for metastatic/recurrent disease.
• Known hypersensitivity reaction to mouse antibodies.
• Patients with nasopharyngeal cancer are excluded.

• ImClone LLC
• National Comprehensive Cancer Network